Login to Your Account

Broad Program, Mixed Results

Cytokinetics' Cancer Bid Iffy, Heart Effort Showing Promise

By Randall Osborne

Monday, July 9, 2007
Casting a wide clinical net has its drawbacks - cost, mainly - and its advantages, such as better chances of finding efficacy. But even the positive point isn't always entirely so, as Cytokinetics Inc. found out late last month, when its good/bad news regarding ispinesib, its kinesin spindle protein (KSP) inhibitor for cancer. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription